{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Germany Diagnostics & Research news", "home_page_url": "https://sharemaestro.com/newsreel/de/healthcare/diagnostics-research/", "feed_url": "https://sharemaestro.com/newsreel/de/healthcare/diagnostics-research/feed.json", "description": "Latest Diagnostics & Research company headlines from Germany, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:cf8f8e2e6dfcace0e6fe8f5af3d77937351bfb2e3ce92051161d225e3ad41307", "url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "external_url": "https://finance.yahoo.com/healthcare/articles/envetec-appoints-patrick-jones-independent-070000390.html", "title": "Envetec Appoints Patrick S. Jones as Independent Director", "content_text": "Envetec Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec's global expansion Patrick S. JonesPatrick S. Jones, President of Thermo Fisher Scientific's Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life sciences, today announced the appointment of Patrick S. Jones, president of Thermo Fisher Scientific", "date_published": "2026-08-14T07:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:6d94a2828794f443fb7600fc36fdf927e9d2536c40861e5a870a9d6ffbb4958c", "url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-danaher-corporation-dhr-bioprocessing-001354402.html", "title": "Could Danaher Corporation (DHR)\u2019s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?", "content_text": "When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower in response. That drop immediately spilled over to Bio-Rad Laboratories, Inc. (NYSE:BIO), holder of a $5 billion strategic stake in Sartorius, sending Bio-Rad shares down about 1% in early New York trading.", "date_published": "2026-08-14T00:13:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:f24688ac4b49aeeb0e4d88979e328a0a6e96e368502d0f733fb24b04fa9f7824", "url": "https://finance.yahoo.com/healthcare/articles/viatris-vtrs-selling-tyrvaya-could-230317847.html", "external_url": "https://finance.yahoo.com/healthcare/articles/viatris-vtrs-selling-tyrvaya-could-230317847.html", "title": "Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?", "content_text": "According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent sales milestone payments. Expected to close in the second half of 2026, the transaction transfers a dry eye disease treatment approved in the U.S., China, and Taiwan to a specialized ophthalmic player, allowing Viatris to streamline its portfolio.Could Danaher Corporat", "date_published": "2026-08-13T23:03:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:1d628b9b8427894cc46575b2ed1469dcee0e3d5e8a188429a826dff1aac3c812", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOQjV6UkxTN044cUUwc0l3YkttbTR1QkRQZ0E0emZ4dEphMldoOU51MXpnVTdqdmNqWWk1azZhZFNkcnZjLXB6bDlfUjFtMzZQYkRSOTl5S0ZfdkEwaXdHVGF5N3NaUC12UWdxSHdMQzRoSXl6WEdZY3l5cldFOUp3SjhMQTV2dkpTWkU1NU96ZjRUOGFMdHRRWVZ6ZEh1VHExVmJiV2llQ1VuYVdDbUxXMkM4RExJdzJxMlJCaTZ4RjNoU3htaVJWNlJUSQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOQjV6UkxTN044cUUwc0l3YkttbTR1QkRQZ0E0emZ4dEphMldoOU51MXpnVTdqdmNqWWk1azZhZFNkcnZjLXB6bDlfUjFtMzZQYkRSOTl5S0ZfdkEwaXdHVGF5N3NaUC12UWdxSHdMQzRoSXl6WEdZY3l5cldFOUp3SjhMQTV2dkpTWkU1NU96ZjRUOGFMdHRRWVZ6ZEh1VHExVmJiV2llQ1VuYVdDbUxXMkM4RExJdzJxMlJCaTZ4RjNoU3htaVJWNlJUSQ?oc=5", "title": "Die Thermo-Fisher-Aktie reagiert auf starke Q2-Zahlen und angehobene Prognose", "content_text": "Die Thermo-Fisher-Aktie reagiert auf starke Q2-Zahlen und angehobene Prognose", "date_published": "2026-08-13T14:49:50+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:85b30a7f57dae1141c5c497a86240aca8d963593b82186f4fc9281f6c0595490", "url": "https://finance.yahoo.com/healthcare/articles/eurofins-cdmo-alphora-expands-kilolab-140000526.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eurofins-cdmo-alphora-expands-kilolab-140000526.html", "title": "Eurofins CDMO Alphora Expands Kilolab and High Potency Development and Manufacturing Capabilities", "content_text": "MISSISSAUGA, Ontario, August 13, 2026--(BUSINESS WIRE)--Eurofins CDMO Alphora has expanded its kilolab and high-potency active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities in Mississauga. The expanded laboratories are designed to support the growing demand for enhanced flexibility as part of process development, scale-up, and manufacturing activities for non-high potent and high potent programs. Together, the suites cover 627 square feet. They are equipped with walk-in fume hoods capable of supporting up to 100L glass reactors and utilise a flexible design so th", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ESF0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ESF0", "name": "Eurofins Scientific SE", "sentiment_url": "https://sharemaestro.com/sentiment/0b5b97e2-6f0c-4512-9962-82c5c6aad9b2/"}]}}, {"id": "source:bc28a49ce510ac5a9ebb23de8819886b9b24d2f299e044b25775aab004164d6e", "url": "https://finance.yahoo.com/healthcare/articles/fda-clearance-qiastat-dx-bloodstream-121034829.html", "external_url": "https://finance.yahoo.com/healthcare/articles/fda-clearance-qiastat-dx-bloodstream-121034829.html", "title": "Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?", "content_text": "Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. On August 10, 2026, the company also secured U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, moving its QIAstat-Dx platform into bloodstream infection diagnostics and reinforcing its effort to offer a broad infectious disease testing menu on one integrated system. We'll now e", "date_published": "2026-08-13T12:10:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QIA", "name": "Qiagen N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/c7c283ff-2c34-4ea9-b775-1ba4cd1e9c0c/"}]}}, {"id": "source:8255e7cf86fc7f7dbf20ba8b05ab36ba147b66fe9dbd15078d59bb275410c8da", "url": "https://finance.yahoo.com/markets/stocks/articles/3-large-cap-stocks-risky-120500749.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/3-large-cap-stocks-risky-120500749.html", "title": "3 Large-Cap Stocks We Find Risky", "content_text": "3 Large-Cap Stocks We Find Risky Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they've already captured significant portions of their markets. This dynamic can trouble even the most skilled investors, but luckily for you, we started StockStory to help you navigate these trade-offs and uncover exceptional companies that break the mold. Keeping that in mind, here are three large-cap stocks whose momentum may slow and a few alternatives yo", "date_published": "2026-08-13T12:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:2dd4be49feba281b049e08a85747f7bdd52c55d23b81c7a35a04371f8a8f139b", "url": "https://finance.yahoo.com/healthcare/articles/strong-q2-2026-results-cardiac-021011441.html", "external_url": "https://finance.yahoo.com/healthcare/articles/strong-q2-2026-results-cardiac-021011441.html", "title": "Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?", "content_text": "IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We'll now examine how the new Catalyst proBNP Test and raised 2026 guidance may reshape IDEXX's broader investment narrative. Capitalize on the AI infrastructure su", "date_published": "2026-08-13T02:10:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:4de41d510eb6b85ba6b7bab47e5d874ee9668bafd394ff2f37adc57dcbc6d752", "url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "external_url": "https://finance.yahoo.com/healthcare/articles/stronger-q2-results-supply-deal-231637512.html", "title": "Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)", "content_text": "LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize ", "date_published": "2026-08-12T23:16:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:514e128ebb8254b2e7833258dba6fdd75fb5811bfb18edc60a79a42420c9a8e5", "url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/livanova-livn-could-5-undervalued-220952454.html", "title": "LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a", "date_published": "2026-08-12T22:09:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:003901eac9af269cec5562f97186cf7b5459ffc496c54fb72170db2160dfcb70", "url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-director-pdmr-shareholding-160000890.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-director-pdmr-shareholding-160000890.html", "title": "Eurofins Scientific: Director/PDMR Shareholding", "content_text": "LUXEMBOURG, August 12, 2026--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\"PDMR\"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventur", "date_published": "2026-08-12T16:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ESF0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ESF0", "name": "Eurofins Scientific SE", "sentiment_url": "https://sharemaestro.com/sentiment/0b5b97e2-6f0c-4512-9962-82c5c6aad9b2/"}]}}, {"id": "source:029b930f20a105a95eaa12cd975b6a874a0df5533dd2b17096e2a683ed2b555d", "url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astorg-completes-acquisition-microbiology-business-121000815.html", "title": "Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist", "content_text": "The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and pharmaceutical markets. The investment reflects Astorg's focused healthcare strategy and distinctive approach to complex transactions, combining deep sector expertise, and a strong track record of operational value creation. Dirk Bontridder has been appointed Chief Executive Officer to lead the company through its next stage of growth, in partnership with Astorg. LUXEMBOURG & NEW YORK & PARIS, August 12, ", "date_published": "2026-08-12T12:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:688dd6155a7cb88c81afaf3dfbc5f3ff71c8943fffdd208b3d801f90606caafe", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-completes-sale-120000581.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-completes-sale-120000581.html", "title": "Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg", "content_text": "WALTHAM, Mass., August 12, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was part of Thermo Fisher's Specialty Diagnostics segment. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260812171039/en/ Contacts Media Contact Information: Sandy Pound Thermo Fisher Scientific Phone: 781-622-1223 E-mail: sandy.pound@thermofisher.com Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1356 E-mail: rafael.tejada@thermofisher.com View Comments", "date_published": "2026-08-12T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:d7ffec6e6848b736b4a9bdaa99baad8cd5c62764060ba7d18bbb63b3adaa648a", "url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "external_url": "https://finance.yahoo.com/healthcare/articles/following-hamamatsus-rebranding-nkt-photonics-112000673.html", "title": "Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030", "content_text": "Company Logo Accelerating momentum across major industry heavyweights\u2014highlighted by Thermo Fisher Scientific's Q2 2026 revenue beat, Hamamatsu Photonics' launch of its dedicated Lasers & Fibers Business Unit, and BD's $4.98 billion Q3 performance\u2014is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics MarketBiophotonics Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"Biophotonics - A G", "date_published": "2026-08-12T11:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:1bf1a09d8e5ed239af1711d1be1d1d1ea675858affeadb586e3289c88f63c03f", "url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "external_url": "https://finance.yahoo.com/healthcare/articles/vitiligo-registry-move-needle-thermo-212006914.html", "title": "Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?", "content_text": "Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter growth engine: the real-world data business tucked inside its lab-services empire, far from the instruments most investors picture when they hear the name.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Growth Machine Bu", "date_published": "2026-08-11T21:20:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:33df7ded49c2f5f4575b1482e58d3b2d84fa1b5dc39c58c6f5ec5b473a7578ca", "url": "https://finance.yahoo.com/markets/stocks/articles/talen-energy-tln-raised-guidance-192349215.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/talen-energy-tln-raised-guidance-192349215.html", "title": "Talen Energy (TLN) Raised Guidance In August, So Why The Loss?", "content_text": "On August 5, Talen Energy (NASDAQ:TLN) posted a net loss for the second quarter, and yet the same release raised the company's full-year 2026 outlook and lifted its expectations for 2027 and 2028. That looks like a contradiction until you separate the accounting from the cash. One line tells you what hit the income statement. The other tells you where the business is actually headed.Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)? Bull Case: A Flywheel Strategy Gaining Speed Adjusted EBITDA came in at $374 million for the quarter, up sharply from $90 million a year earlier,", "date_published": "2026-08-11T19:23:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:8c3210a2efed1a915d0aaa5cca0de5722694e6134cc5a4c6b87354a602e65942", "url": "https://finance.yahoo.com/markets/stocks/articles/idexx-idxx-q2-2026-earnings-162815512.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/idexx-idxx-q2-2026-earnings-162815512.html", "title": "IDEXX (IDXX) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike Erickson Chief Financial Officer - Andrew Emerson Vice President, Investor Relations - John Ravis Full Conference Call Transcript Operator: Good morning, and welcome to the IDEXX Laboratories Second Quarter 2026 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Mike Erickson, President and Chief Executive Officer; Andrew Emerson, Chief Financial Officer; and John Ravis, Vice President, In", "date_published": "2026-08-11T16:28:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:b1ec97d8ba6c60560d249e3a914f3e90a2f9ec37e343892cb2c5f9899574816a", "url": "https://finance.yahoo.com/healthcare/articles/integrated-dna-technologies-scientists-set-125300711.html", "external_url": "https://finance.yahoo.com/healthcare/articles/integrated-dna-technologies-scientists-set-125300711.html", "title": "Integrated DNA Technologies Scientists Set New Performance Benchmark for CRISPR Off-Target Nomination", "content_text": "Nature Communications study finds UNCOVERseq\u2122 delivered the strongest combined sensitivity and precision among evaluated CRISPR off-target nomination methods Findings provide a more rigorous framework for prioritizing potential off-target sites for confirmation and safety assessment in CRISPR-based therapeutic development, supporting more confident progress from promising science toward responsible therapeutic impact Study defines sequencing, replication and process-control conditions relevant to emerging regulatory expectations for genome-editing safety studies CORALVILLE, Iowa, August 11, 20", "date_published": "2026-08-11T12:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:5c6a39778f3067627cb7bc3a54e6b94141910a440f639598b5d84d1518ddcad7", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-collaborates-michael-123000003.html", "title": "Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson\u2019s Precision Medicine", "content_text": "Olink\u2122 Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approximately 5,500 research samples were analyzed using Olink technology. Access: The resulting data are available to researchers in PPMI's repository. Purpose: The dataset may help researchers study Parkinson's biology, patient subtypes, disease progression and potential biomarkers. Impact: The resource supports prec", "date_published": "2026-08-11T12:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:849fd66286a023448d721155eb77b3e4932666b084bce0e7349369ce07939314", "url": "https://finance.yahoo.com/healthcare/articles/idexx-expands-catalyst-platform-cardiac-110000498.html", "external_url": "https://finance.yahoo.com/healthcare/articles/idexx-expands-catalyst-platform-cardiac-110000498.html", "title": "IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test", "content_text": "New test brings quantitative cardiac assessment for cats and dogs into everyday workflows WESTBROOK, Maine, August 11, 2026--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst\u2122 proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cat", "date_published": "2026-08-11T11:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:087d578d3f75d830d50d54bbb4f31de98eb6f9576d94fb132b7fae0ab08fa04b", "url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "external_url": "https://finance.yahoo.com/healthcare/articles/non-viral-transfection-reagents-market-084500474.html", "title": "Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific", "content_text": "Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035\" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in", "date_published": "2026-08-11T08:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:730e791a1d866207073404b567adedd77212ff66564ad5faeb97fe9fcaf449ac", "url": "https://finance.yahoo.com/healthcare/articles/qiagen-receives-u-fda-clearance-200500942.html", "external_url": "https://finance.yahoo.com/healthcare/articles/qiagen-receives-u-fda-clearance-200500942.html", "title": "QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel", "content_text": "QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel family Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting about 1.7 million adults annually in the U.S., underscoring the need for rapid detection GERMANTOWN, Md. & VENLO, Netherlands, August 10, 2026--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard:", "date_published": "2026-08-10T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QIA", "name": "Qiagen N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/c7c283ff-2c34-4ea9-b775-1ba4cd1e9c0c/"}]}}, {"id": "source:c27320e8ca02985c9f1c86b98dd29b4b9a258173202b95b8fabee03750fbf62c", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-gain-afternoon-195804577.html", "title": "Sector Update: Healthcare Stocks Gain Late Afternoon", "content_text": "Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-10T19:58:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:a154841a20179ab408369874e9631ab5bb694429f8d159cb1e5aa9d93a3b4a48", "url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "external_url": "https://finance.yahoo.com/healthcare/articles/investors-reacting-thermo-fisher-scientific-191508215.html", "title": "How Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform", "content_text": "In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S, Thermo Fisher is deepening its role in linking high-complexity diagnostics with streamlined lab workflows and more standardized ", "date_published": "2026-08-10T19:15:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:6038f22aad4fd393cbbf01648401cd7f87962e69d81d7f61d81eef7db7c5ad36", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-rise-afternoon-174031450.html", "title": "Sector Update: Healthcare Stocks Rise in Afternoon Trading", "content_text": "Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-10T17:40:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:5818ef853474232e6c61f0a1f12e526b9b96cbcdb99063ae6e75eca3141d2f88", "url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-se-weekly-report-154500724.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-se-weekly-report-154500724.html", "title": "Eurofins Scientific SE: Weekly Report on Share Repurchases from 03rd August to 07th August 2026", "content_text": "LUXEMBOURG, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 03/08/2026 FR0014000MR3 20 000 68.4085 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 04/08/2026 FR0014000MR3 20 000 68.6892 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 05/08/2026 FR0014000MR3 20 000 69.4244 XPAR EUROFINS SCIENTIFIC 529900JEHF", "date_published": "2026-08-10T15:45:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ESF0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ESF0", "name": "Eurofins Scientific SE", "sentiment_url": "https://sharemaestro.com/sentiment/0b5b97e2-6f0c-4512-9962-82c5c6aad9b2/"}]}}, {"id": "source:9e58f00db4a3c14a6599f730a1a3d86b058a3a60927aaebf2b9c2df7c34b5140", "url": "https://finance.yahoo.com/markets/stocks/articles/understanding-qiagen-qgen-reliance-international-131511002.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/understanding-qiagen-qgen-reliance-international-131511002.html", "title": "Understanding Qiagen (QGEN) Reliance on International Revenue", "content_text": "Have you assessed how the international operations of Qiagen (QGEN) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this unde", "date_published": "2026-08-10T13:15:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "QIA"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "QIA", "name": "Qiagen N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/c7c283ff-2c34-4ea9-b775-1ba4cd1e9c0c/"}]}}, {"id": "source:7d42e5de72d8e05ded5a67927f837f9d18ccae9f4339f1e05381a1c970df3cf4", "url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-se-disclosure-total-130700997.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/eurofins-scientific-se-disclosure-total-130700997.html", "title": "Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 July 2026", "content_text": "LUXEMBOURG, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF) EUROFINS SCIENTIFIC SE \u2013 E1013 2. Identity of the notifier (if another person makes the notification on behalf of the issuer) N/A 3. Total", "date_published": "2026-08-10T13:07:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ESF0"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ESF0", "name": "Eurofins Scientific SE", "sentiment_url": "https://sharemaestro.com/sentiment/0b5b97e2-6f0c-4512-9962-82c5c6aad9b2/"}]}}, {"id": "source:309a29f5c028e2baf45de118523760972e80d1f8e0c912e8ede47a96913c6a6c", "url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/beat-market-zacks-aveanna-factset-123400629.html", "title": "Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus", "content_text": "Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. economic outlook, expectations for a supportive Federal Reserve policy environment and easing concerns about inflation. Strong corporate earnings also helped reinforce confidence in the market's growth prospects. Technology and growth-oriented sectors led the advance, boosting the Nasdaq, while broader participation suppo", "date_published": "2026-08-10T12:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:cf5876587718bd1c845e6d6d2f5587edbccd20aa96ef6b42f35f990578eb1131", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "external_url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-tmo-vs-danaher-000131616.html", "title": "Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?", "content_text": "Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher's (NYSE:DHR) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?Top Long-Term Biotechnology Stocks", "date_published": "2026-08-10T00:01:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "TN8", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}, {"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:9e54beb49bd734ca4059a93d1296e94e02f07b216dd32260f8c823b96a33ec3b", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE9mSkRHOTNJam5PLVZoSUVHRnF3a3B0QnpzSDkzbVpla0tzMlpSUUFkWHRYcXR4czFDcHFRQUhEbExDODM3SUlUUFFsdHhnOGwwNTZ0OGZUVFhqYVFQMUFVaTJQcw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE9mSkRHOTNJam5PLVZoSUVHRnF3a3B0QnpzSDkzbVpla0tzMlpSUUFkWHRYcXR4czFDcHFRQUhEbExDODM3SUlUUFFsdHhnOGwwNTZ0OGZUVFhqYVFQMUFVaTJQcw?oc=5", "title": "Thermo Fisher Scientific Inc (TMO) Aktuelle Aktien-News", "content_text": "Thermo Fisher Scientific Inc (TMO) Aktuelle Aktien-News", "date_published": "2026-08-08T10:12:18+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:0502d5eef2fdb42109548ad3ff8f999b7338348938e4086546946336cfb33483", "url": "https://seekingalpha.com/news/4628212-catalyst-watch-inflation-reads-amat-earnings-google-pixel-event-and-mlb-on-netflix?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4628212-catalyst-watch-inflation-reads-amat-earnings-google-pixel-event-and-mlb-on-netflix?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix", "content_text": "[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - AUGUST 10 * VOLATILITY WATCH - SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Rocket Lab (RKLB [https://seekingalpha.com/symbol/RKLB]) have seen options volatility increase over the last week. The most overbought stocks per their 14-day relative strength index include SMJ International (SMJF [https://seekingalpha.com/symbol/SMJF]), Chime Fin", "date_published": "2026-08-07T19:00:38+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:e40591a6fdb9510d51c0a84584f19647c003c14ca3bf5c16c407aa32e2af130f", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9kWS1CX1owdmR4cWlPMXVUWk1mM1dHbG1pLUhWeEY3eWRld29Jc0NFdWRzY3Y3bDdJUnpSLVNPMml0SVlaVUhud1JVbVlSTnVCNW13RmdDM2kwWVpQeGRDcXpMU0tYTTNaQnc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9kWS1CX1owdmR4cWlPMXVUWk1mM1dHbG1pLUhWeEY3eWRld29Jc0NFdWRzY3Y3bDdJUnpSLVNPMml0SVlaVUhud1JVbVlSTnVCNW13RmdDM2kwWVpQeGRDcXpMU0tYTTNaQnc?oc=5", "title": "IDEXX Laboratories Inc (IDXX) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "content_text": "IDEXX Laboratories Inc (IDXX) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "date_published": "2026-08-07T09:38:41+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:abd1eb56b78b15d182a8068156f6b43de3d557fc0c0b213440cc59a3f539030c", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQWFlNRTl2WGtsNWJRWWNrckJ5OEpSVHJDZ3hqYnRPZjRvMGI1NkJGTTZ5NXh5emRTbnlJNDA2UHUtQlNSdUdveEM1empFMEFnV2dlRV9qZE4zTmVQalNKS1ZlTHhOcXFxaHBYUnduTTY5RTh0d2pSblE0cnNPQXI4ZFRCcDBueFFqUUhEMUZiTE9wRHRrdE1ZNE1iNkJsR0cyd2tvTEFhTjNRVkJITHdPQmw5dkxqZVNIUkE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQWFlNRTl2WGtsNWJRWWNrckJ5OEpSVHJDZ3hqYnRPZjRvMGI1NkJGTTZ5NXh5emRTbnlJNDA2UHUtQlNSdUdveEM1empFMEFnV2dlRV9qZE4zTmVQalNKS1ZlTHhOcXFxaHBYUnduTTY5RTh0d2pSblE0cnNPQXI4ZFRCcDBueFFqUUhEMUZiTE9wRHRrdE1ZNE1iNkJsR0cyd2tvTEFhTjNRVkJITHdPQmw5dkxqZVNIUkE?oc=5", "title": "Clinical Visits Keep Falling. IDEXX Laboratories\u2019 Q2 Earnings Report Say That Doesn\u2019t Matter.", "content_text": "Clinical Visits Keep Falling. IDEXX Laboratories\u2019 Q2 Earnings Report Say That Doesn\u2019t Matter.", "date_published": "2026-08-07T06:14:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:7ee65a55d28c94103e6575c55aaf137fd00dc6b0966dd693a56b9371f8f65c97", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Werden die neue EXENT-Myelom-Plattform von Thermo Fisher (TMO) und die Ergebnisse des zweiten Quartals die Einsch\u00e4tzung des Unternehmens im Diagnostikbereich ver\u00e4ndern?", "content_text": "Werden die neue EXENT-Myelom-Plattform von Thermo Fisher (TMO) und die Ergebnisse des zweiten Quartals die Einsch\u00e4tzung des Unternehmens im Diagnostikbereich ver\u00e4ndern?", "date_published": "2026-08-06T14:54:11+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:147da6bd168e77eeffb85bb0f79bae5253b8ec4447308f59a37063324bc80e8b", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPMldBVVRrYUFEdkh1VmgxaVZ2WlRNNkdnNnFyUTV4MGFVblJqZWFPX0Z3Y29UdWFTdmRuaGUyY0VlMmpIclFrMFdTa3U4bzNJT25paU9TOXNaNHlpdmMtbE0zTWtOZm1IV3JHeU40VEU2RXBTR2FObko0U3dDajZVY1pUb3ZTU0RDQ2N2clI0OVV5czNjN1FKb3AzUmtNd2ptMHlWZjRhYWM5NThUS2c?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPMldBVVRrYUFEdkh1VmgxaVZ2WlRNNkdnNnFyUTV4MGFVblJqZWFPX0Z3Y29UdWFTdmRuaGUyY0VlMmpIclFrMFdTa3U4bzNJT25paU9TOXNaNHlpdmMtbE0zTWtOZm1IV3JHeU40VEU2RXBTR2FObko0U3dDajZVY1pUb3ZTU0RDQ2N2clI0OVV5czNjN1FKb3AzUmtNd2ptMHlWZjRhYWM5NThUS2c?oc=5", "title": "Thermo Fisher Stock Clawed Back From a 31% Slide. A Guidance Raise May Explain Why.", "content_text": "Thermo Fisher Stock Clawed Back From a 31% Slide. A Guidance Raise May Explain Why.", "date_published": "2026-08-06T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Guidance", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:93e3bd8f014928ea563caec94026a5a99baee02994a825eaab0942505b09fdba", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE4tWTBUQzdFbWQzbFdOczI3bTZ4YkNZR3RadTRyUzE5bm1NLXJWdjN6SmR0b2VGNGkxenRlQnRqMVlEOXNNUXBSNkF3Z09fMUdkZTFpc2dWRFNIM2JXWUNxQzl6cFFGZHhTWEdN?oc=5", "external_url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE4tWTBUQzdFbWQzbFdOczI3bTZ4YkNZR3RadTRyUzE5bm1NLXJWdjN6SmR0b2VGNGkxenRlQnRqMVlEOXNNUXBSNkF3Z09fMUdkZTFpc2dWRFNIM2JXWUNxQzl6cFFGZHhTWEdN?oc=5", "title": "IDEXX Laboratories Inc. Aktie: Bilanz & Finanzlage | Goldesel", "content_text": "IDEXX Laboratories Inc. Aktie: Bilanz & Finanzlage | Goldesel", "date_published": "2026-07-30T21:17:09+00:00", "authors": [{"name": "Goldesel.de"}], "tags": ["Market update", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:e41a013f7c9cf567013a0acb8c26c234d07539ad56486b69959f3c1ab0828f45", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Warum Thermo Fisher Scientific (TMO) nach \u00fcber den Erwartungen liegenden Ergebnissen im zweiten Quartal, dem Abschluss des Aktienr\u00fcckkaufs und der Markteinf\u00fchrung von InstaFlux um 6,7 % gestiegen ist", "content_text": "Warum Thermo Fisher Scientific (TMO) nach \u00fcber den Erwartungen liegenden Ergebnissen im zweiten Quartal, dem Abschluss des Aktienr\u00fcckkaufs und der Markteinf\u00fchrung von InstaFlux um 6,7 % gestiegen ist", "date_published": "2026-07-26T23:39:48+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:f1a724b65a69c0e2230b0994a6433c808e5603f061905fe1d717b56934ebedea", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOTU1KdjgwV1JlRVg1Ym9oOWNDTF9PRndPQlJSNkhOazFnRHlFblc1UHFRUWxZTVNjWjE0UVI1ZnpGRWZBbEZQRlM2MDlxbFhkS0cwNmZhNzhMOEpxVEdoLVl0V0hiWXZOVmxRTlhqdTNlQmlYWnlWSnpaNGhUOE8zWUVrWmRBcUtjMkJ4UG9fVTgwS3Y3U05XclhCeG93UWM1?oc=5", "external_url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOTU1KdjgwV1JlRVg1Ym9oOWNDTF9PRndPQlJSNkhOazFnRHlFblc1UHFRUWxZTVNjWjE0UVI1ZnpGRWZBbEZQRlM2MDlxbFhkS0cwNmZhNzhMOEpxVEdoLVl0V0hiWXZOVmxRTlhqdTNlQmlYWnlWSnpaNGhUOE8zWUVrWmRBcUtjMkJ4UG9fVTgwS3Y3U05XclhCeG93UWM1?oc=5", "title": "Danaher Aktie: 1,94 Dollar EPS schl\u00e4gt Erwartung", "content_text": "Danaher Aktie: 1,94 Dollar EPS schl\u00e4gt Erwartung", "date_published": "2026-07-26T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Earnings", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:501e7d35b596707cae535c0a06e4c5f993084d6e8be5ed5b3336c497d694b31d", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUVd1RzdfVC1TOVozc0ZvZG9VWV9ic0FBNHRBSmN1bWhqQld0YXllcFNDampGRzhOLWd2V1BIdDJKZmctd0xmNlFhcUxfdjF6Y0RtZUwyYURhNUMzQVpRbXZuVXVMVVlDV1haMm51T2VMUTIyM0NHekpXNW85WDZYM3NHQzNvZFJmZjBBbzd5LTBwcDlMdDVqdm1MQ2RmQnE2X25XcA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUVd1RzdfVC1TOVozc0ZvZG9VWV9ic0FBNHRBSmN1bWhqQld0YXllcFNDampGRzhOLWd2V1BIdDJKZmctd0xmNlFhcUxfdjF6Y0RtZUwyYURhNUMzQVpRbXZuVXVMVVlDV1haMm51T2VMUTIyM0NHekpXNW85WDZYM3NHQzNvZFJmZjBBbzd5LTBwcDlMdDVqdm1MQ2RmQnE2X25XcA?oc=5", "title": "Thermo Fisher Raised Full-Year Guidance After a Standout Q2 Earnings Call", "content_text": "Thermo Fisher Raised Full-Year Guidance After a Standout Q2 Earnings Call", "date_published": "2026-07-24T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:55c9df263b0be06a78ba76cf33ba75d3043f6e7375aa0374540fa30bce3d9438", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZTIwYW9SWmtKTWh0Z1hhcjFGX0N1TDJBTVJqMnN6a0lmUXlWbWJ4VHhzSUNmajRBWDh2ak8zbUJ2VW1hVlVabUlYbElPQkRqeEhXZWNNUDR0UVViNWhfeEo0Y011c2J1TTQwQ0VoZ2UydzRlSlloQUl4QVd1ZFJDem41RTdCVHdfdnV0NW5XZVVpOVQwVEtXVTU0azFsMmdBaEc3QzN5U0lPOGNKbDBiVmpBSUY1N1ExRmJNNkhFM0pRWGlFMFRnZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZTIwYW9SWmtKTWh0Z1hhcjFGX0N1TDJBTVJqMnN6a0lmUXlWbWJ4VHhzSUNmajRBWDh2ak8zbUJ2VW1hVlVabUlYbElPQkRqeEhXZWNNUDR0UVViNWhfeEo0Y011c2J1TTQwQ0VoZ2UydzRlSlloQUl4QVd1ZFJDem41RTdCVHdfdnV0NW5XZVVpOVQwVEtXVTU0azFsMmdBaEc3QzN5U0lPOGNKbDBiVmpBSUY1N1ExRmJNNkhFM0pRWGlFMFRnZw?oc=5", "title": "Danaher hebt EPS-Prognose nach Q2 an: Bioprocessing dr\u00fcckt, Aktie blei", "content_text": "Danaher hebt EPS-Prognose nach Q2 an: Bioprocessing dr\u00fcckt, Aktie blei", "date_published": "2026-07-23T07:00:00+00:00", "authors": [{"name": "Goldesel.de"}], "tags": ["Market update", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:e39e3431f031bd132b4f3418dc3b25e7240492ccd30d91080409fa2d39d45f48", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxONE1mYmV5cS1ZbXFPenJ5aXh4cFFBTXlxRXhnRVRpajJZb3pIbHR0VTdwRWo5b0JkSW5BYXNlN3BuZ3JCWEFyYlVIWUI3cWpjWmt0TngwVTZsVnZ5YWthY1hHZC10VUUwNEoyTFlsekl2N1RvYVppc05qN21zSzc1ZWVhZ3lXclRYeFRLN2t3UnZKMC1tMnkwZm5rSVRsbmtuandKR0VwbkhkWWdSUDQ5M3k5dllrSTRDWnpPQ0M1T3ZqelUyRlM1cUVn?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxONE1mYmV5cS1ZbXFPenJ5aXh4cFFBTXlxRXhnRVRpajJZb3pIbHR0VTdwRWo5b0JkSW5BYXNlN3BuZ3JCWEFyYlVIWUI3cWpjWmt0TngwVTZsVnZ5YWthY1hHZC10VUUwNEoyTFlsekl2N1RvYVppc05qN21zSzc1ZWVhZ3lXclRYeFRLN2t3UnZKMC1tMnkwZm5rSVRsbmtuandKR0VwbkhkWWdSUDQ5M3k5dllrSTRDWnpPQ0M1T3ZqelUyRlM1cUVn?oc=5", "title": "Danaher-Aktie f\u00e4llt nach Masimo-Schluss trotz angehobener Prognose: Wa", "content_text": "Danaher-Aktie f\u00e4llt nach Masimo-Schluss trotz angehobener Prognose: Wa", "date_published": "2026-07-21T07:00:00+00:00", "authors": [{"name": "Goldesel.de"}], "tags": ["Market update", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:e0314b1343687afdbf6deffbd1466a4077ced47fe7627ff2e1a3e104033d3c45", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNUzZZZXpSU1ktMHhLR1F6bF9tWG05Z3NCamlmZW5RMUg2OGw5aGtLSFRkOFBBUkhaaGNudDBLYnRrcGs4eXM3MjJRYnpFRmJnVk0wX3B0SW1sNjB4aENROEhtSm1hcVZPb2hLLXhILW5KSkl5NGo2X0d3dkJlSEV5aVNXTVZDeTA1XzAxOXprUGRVdHk5bDNpYQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNUzZZZXpSU1ktMHhLR1F6bF9tWG05Z3NCamlmZW5RMUg2OGw5aGtLSFRkOFBBUkhaaGNudDBLYnRrcGs4eXM3MjJRYnpFRmJnVk0wX3B0SW1sNjB4aENROEhtSm1hcVZPb2hLLXhILW5KSkl5NGo2X0d3dkJlSEV5aVNXTVZDeTA1XzAxOXprUGRVdHk5bDNpYQ?oc=5", "title": "Danaher Aktie: EPS erwartet bei 1,84 Dollar", "content_text": "Danaher Aktie: EPS erwartet bei 1,84 Dollar", "date_published": "2026-07-18T07:00:00+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Earnings", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:fcbc59ae35bc8415ae9407a117da4ce55b4e225d1050f90b70d12717f965a009", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbDhfcHFXTjZJWks5VEEzbHN1N2p4Qi1IQmlKdVRNaTVlUC1wajFLYzRubU5zcmFBbU9kaERyVTA4QXBvdFpWQXVqYkROVW1BbEJDbHV5clZxUC1GZ0Y5XzlYWFNUYWNOSGVxSE54cEpEa2Nha1hiNWxZVXlKRm95a3ljT3VSRnk1T2t5Q1hZWm9HMlhtU0t2OTRITXJIWFdRZXhod1J5eDNWVnEwdm9kRzEzajVkUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbDhfcHFXTjZJWks5VEEzbHN1N2p4Qi1IQmlKdVRNaTVlUC1wajFLYzRubU5zcmFBbU9kaERyVTA4QXBvdFpWQXVqYkROVW1BbEJDbHV5clZxUC1GZ0Y5XzlYWFNUYWNOSGVxSE54cEpEa2Nha1hiNWxZVXlKRm95a3ljT3VSRnk1T2t5Q1hZWm9HMlhtU0t2OTRITXJIWFdRZXhod1J5eDNWVnEwdm9kRzEzajVkUQ?oc=5", "title": "IDEXX Laboratories Stock: $876 Target Backed by Cancer Dx Adoption Across 7,500 Practices", "content_text": "IDEXX Laboratories Stock: $876 Target Backed by Cancer Dx Adoption Across 7,500 Practices", "date_published": "2026-07-06T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Analyst action", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:3496016e997e7235f4e6d17e8ed7d730c37a9a556527490b5cd420178028d41b", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQTlwSjY1NTJNamNTakpUcEpZMGg0TEUtVlAwRDkyVG5nbEZGdEwyMDNKR1U2bWphd3JRcURPc0xCdnUzenBIMXBzWVNzTmRQdEFqQ1FPeElwNVBZUkpaVHJHY3B1MThiY0tnQzBxemJ5TWNyVkk3aHpmNlEzNHB5WEMySjA4alQxeGNVNzNFR0lnc2VBRGFQcFF6MDc5Yng1cE9GdmFDMEFOb1hVMGJwajFEdlpIcG5FcklBWk1ycHZYZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQTlwSjY1NTJNamNTakpUcEpZMGg0TEUtVlAwRDkyVG5nbEZGdEwyMDNKR1U2bWphd3JRcURPc0xCdnUzenBIMXBzWVNzTmRQdEFqQ1FPeElwNVBZUkpaVHJHY3B1MThiY0tnQzBxemJ5TWNyVkk3aHpmNlEzNHB5WEMySjA4alQxeGNVNzNFR0lnc2VBRGFQcFF6MDc5Yng1cE9GdmFDMEFOb1hVMGJwajFEdlpIcG5FcklBWk1ycHZYZw?oc=5", "title": "Thermo Fisher Stock Trades at $513 While Wall Street Sets a $596 Target: What the EPS Ramp Reveals", "content_text": "Thermo Fisher Stock Trades at $513 While Wall Street Sets a $596 Target: What the EPS Ramp Reveals", "date_published": "2026-06-28T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:4507999bad8dbf76b95386b466da6e9d3af35743af76186e44d3df62132bf7b4", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQb214czRsTEF3Nk5aNkJTUjdsc2otSWJZUEV1R0pPTmJnblJaYVRPcUJPZnJjclhBN2trUjV6VEhEdmNhT0t1N0dEZ1ZUQmFxZHRDZUE3TzdaZTA5XzFBazBDeEtkRWp5VjlFSFRlUU16Q25OdE1SUGdXWjBiT1h2YTdjVkFaaVVFREVQa1lzb2p4Z3BEdlEzeWlCTFBiSE9WZnN4TkZERGdzRER2X2VWZHZvellmcDA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQb214czRsTEF3Nk5aNkJTUjdsc2otSWJZUEV1R0pPTmJnblJaYVRPcUJPZnJjclhBN2trUjV6VEhEdmNhT0t1N0dEZ1ZUQmFxZHRDZUE3TzdaZTA5XzFBazBDeEtkRWp5VjlFSFRlUU16Q25OdE1SUGdXWjBiT1h2YTdjVkFaaVVFREVQa1lzb2p4Z3BEdlEzeWlCTFBiSE9WZnN4TkZERGdzRER2X2VWZHZvellmcDA?oc=5", "title": "Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15", "content_text": "Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15", "date_published": "2026-06-25T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "IX1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IX1", "name": "IDEXX Laboratories, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/161f8f4c-8f39-4209-aee1-c19bb6d55ad5/"}]}}, {"id": "source:45509b296ef2beec5a8943d322f5342a2f2955be5bab17629959159669048041", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPemdhZ0tyTW16azc3X2dOaWhZNUtIdkRGRkRlWlItZnVqREpLcHl2TXIycmtnUDQ0VzBUWDlNWldtay1vNW96SElySW1KRkwwY1RfbFJ2QlNVT1QtQmphR2hpM05YNnczYU83VEUxdmZKakNfYnZxY2hmTFI1cG54T0cwQWVRb0ZaTlBmZ3J0VzBKSzVPRGFmc1BRXzl0OVpCaGhwMk5zb3VnYWlyWHdZOGZxenhpOXl2ZnJVVHVJN0ExdUV1Y1E?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPemdhZ0tyTW16azc3X2dOaWhZNUtIdkRGRkRlWlItZnVqREpLcHl2TXIycmtnUDQ0VzBUWDlNWldtay1vNW96SElySW1KRkwwY1RfbFJ2QlNVT1QtQmphR2hpM05YNnczYU83VEUxdmZKakNfYnZxY2hmTFI1cG54T0cwQWVRb0ZaTlBmZ3J0VzBKSzVPRGFmc1BRXzl0OVpCaGhwMk5zb3VnYWlyWHdZOGZxenhpOXl2ZnJVVHVJN0ExdUV1Y1E?oc=5", "title": "Thermo Fisher Is Down 27% From Its Highs. The EPS Trough Looks Like It Is Already Behind the Company", "content_text": "Thermo Fisher Is Down 27% From Its Highs. The EPS Trough Looks Like It Is Already Behind the Company", "date_published": "2026-06-24T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:5f63d0c39d2238d8ff33c2e082a5d94eb37fb6c03d66c01894bb3df27fc92116", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPeTE3eVRTUjhYX1Bjem1lZ2lOSDdZdWtpZ0tzNThtOTZoTUo3dGlJajFxelBuMkpseFhjRHhpQl9QVmNSQlFHNFRIZ0FJVFdzVzBRNHhuN25HWHlCdVdlRkNHRDlnVTZnaFZTZ3pURXIzTjRhLS1CSUg5OWphNGh0b2FoSHdsMklRZ1FYMFFlN1FVWkFRdG9MTks5VG9NS2ZpR2RvakNEZVl4d2kx?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPeTE3eVRTUjhYX1Bjem1lZ2lOSDdZdWtpZ0tzNThtOTZoTUo3dGlJajFxelBuMkpseFhjRHhpQl9QVmNSQlFHNFRIZ0FJVFdzVzBRNHhuN25HWHlCdVdlRkNHRDlnVTZnaFZTZ3pURXIzTjRhLS1CSUg5OWphNGh0b2FoSHdsMklRZ1FYMFFlN1FVWkFRdG9MTks5VG9NS2ZpR2RvakNEZVl4d2kx?oc=5", "title": "Thermo Fisher Scientific Stock: Why Analyst Consensus Is 27 Buys With Zero Sells", "content_text": "Thermo Fisher Scientific Stock: Why Analyst Consensus Is 27 Buys With Zero Sells", "date_published": "2026-05-30T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Analyst action", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}, {"id": "source:11b797499b0a28a17b540d24056fa31a9677f94a8ac3164dc7513d828b442d21", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNUlNFZkFCWHZpX2sxQVRaMlVHQW9zaDF5NURIbVNJRjZEaTVHU19PbEpGbnZCZ1dVcEFYZ0hjelJkYW91dWZjU2syekVseDVfQ1liX1hCZGgxQ2pPd29yNmNIZ1lBRGpRNGY0SFdWWDlmZVNma3RvM2hJa2w2TnotX2JrcEo0cE1PWUwxRlZzMDhaSHE5bmdpalI1Rno2UGRCYUg0eG1RUjQ1aldzd1djaTJEYl95YnZ2UDl5OUtEcks?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNUlNFZkFCWHZpX2sxQVRaMlVHQW9zaDF5NURIbVNJRjZEaTVHU19PbEpGbnZCZ1dVcEFYZ0hjelJkYW91dWZjU2syekVseDVfQ1liX1hCZGgxQ2pPd29yNmNIZ1lBRGpRNGY0SFdWWDlmZVNma3RvM2hJa2w2TnotX2JrcEo0cE1PWUwxRlZzMDhaSHE5bmdpalI1Rno2UGRCYUg0eG1RUjQ1aldzd1djaTJEYl95YnZ2UDl5OUtEcks?oc=5", "title": "Danaher Stock Forecast 2026: The Bioprocessing Equipment Cycle Has Started and Few Are Watching", "content_text": "Danaher Stock Forecast 2026: The Bioprocessing Equipment Cycle Has Started and Few Are Watching", "date_published": "2026-05-19T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Guidance", "DAP"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DAP", "name": "Danaher Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/934224bc-4546-4828-b955-89cad41498f8/"}]}}, {"id": "source:55260d0d106b4ccfd1c9e59d3fa89749d1272c5d73124bcd51dc0f73942143b9", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxObkJ4NVlvZ29GalVfV0tueDEyQ21EWTUxclNFaV9zdy1yRkdLMWoyY1hGRlAxejlBeEVnT213NnNQRjFWNGV3eUVxVC1sQVNqWlJlazJqLVdXak8wSmFkQmEzTGpxZWY0b0JYVEtHWUMzdFlXenhGY1FENlh4UVRNS01neW40c2NLLXpiOEpsTERzSVpadU1nQUdmdlhFYWVGYzZCZlpNQWhqZU5OeE9nZDhmNEE1QlFJdmFhTm5XR0JfS2FET2hSSjJSN3Z3bllRRjNz?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxObkJ4NVlvZ29GalVfV0tueDEyQ21EWTUxclNFaV9zdy1yRkdLMWoyY1hGRlAxejlBeEVnT213NnNQRjFWNGV3eUVxVC1sQVNqWlJlazJqLVdXak8wSmFkQmEzTGpxZWY0b0JYVEtHWUMzdFlXenhGY1FENlh4UVRNS01neW40c2NLLXpiOEpsTERzSVpadU1nQUdmdlhFYWVGYzZCZlpNQWhqZU5OeE9nZDhmNEE1QlFJdmFhTm5XR0JfS2FET2hSSjJSN3Z3bllRRjNz?oc=5", "title": "Thermo Fisher Stock Down 31% From Its 52-Week High Despite Raising Full-Year EPS Guidance. Here\u2019s What Happened", "content_text": "Thermo Fisher Stock Down 31% From Its 52-Week High Despite Raising Full-Year EPS Guidance. Here\u2019s What Happened", "date_published": "2026-05-19T07:00:00+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "TN8"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TN8", "name": "Thermo Fisher Scientific Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b73857fb-1f05-405e-b33f-d77ffc003685/"}]}}]}